Considering the critical role of the MRTF-SRF pathway in the survival of chemoresistant AML cells, the combination of cytarabine with Rho-MRTF-SRF inhibitors could be a promising therapeutic approach for hematological malignancies. The gene discussed is SRF; the disease is acute myeloid leukemia.